Liquid Biopsy in Non-Small Cell Lung Cancer: Highlights and Challenges.

ABSTRACT: Non-small cell lung cancer is one leading cause of death worldwide, and patients would greatly benefit from an early diagnosis. Since targeted and immunotherapies have emerged as novel approaches for more tailored treatments, repeated assessments of the tumor biology have become pivotal to drive clinical decisions. Currently, tumor tissue biopsy is the gold standard to investigate potentially actionable biomarkers, but this procedure is invasive and may prove inadequate to represent the whole malignancy. In this regard, liquid biopsy represents a minimally invasive and more comprehensive option for early detection and investigation of this tumor. Today, cell-free DNA is the only approved circulating marker to select patients for a targeted therapy. Conversely, the other tumor-derived marke

SUBMITTER: Rijavec E 

PROVIDER: S-EPMC7017364 | biostudies-literature | 2019 Dec

REPOSITORIES: biostudies-literature